LUM-201 (ibutamoren, formerly MK-0677) Trials for Pediatric Growth Hormone Deficiency

madman · Dec 11, 2022

Lumos Pharma KOL Webinar Discussing Interim Results from Two Phase 2 LUM-201 Trials for Pediatric Growth Hormone Deficiency - LifeSci Events

Join us for a virtual KOL Event with Lumos Pharma, featuring Fernando Cassorla, M.D. (University of Chile) and Andrew Dauber, M.D., M.M.Sc. (Children’s National Hospital) who will discuss Lumos Pharma’s investigational drug LUM-201 as…

lifescievents.com

Lumos Pharma KOL Webinar Discussing Interim Results from Two Phase 2 LUM-201 Trials for Pediatric Growth Hormone Deficiency

madman · Dec 11, 2022

madman · Dec 11, 2022

madman · Dec 11, 2022

madman · Dec 11, 2022

madman · Dec 11, 2022

madman · Dec 11, 2022

madman · Dec 11, 2022

madman · Dec 11, 2022

madman · Dec 11, 2022

madman · Dec 11, 2022

madman · Dec 11, 2022

madman · Dec 11, 2022

madman · Dec 11, 2022

LUM-201 (ibutamoren, formerly MK-0677) - Excel Male TRT Forum

www.excelmale.com

madman · Dec 11, 2022

LUM-201 ibutamoren Elicits Greater GH Response Than Standard GH Secretagogues in PGHD - Excel Male TRT Forum

Objective To compare GH responses to an oral GH secretagogue, LUM-201 (ibutamoren, formerly MK-0677) and standard GH stimulation tests used for diagnosis of pediatric growth hormone deficiency (PGHD) Introduction LUM-201 is an orally administered agonist of the growth hormone secretagogue...

www.excelmale.com

madman · Jan 29, 2023

Oral Treatment for Rare Disease Pediatric Growth Hormone Deficiency - Excel Male TRT Forum

https://empoweredpatientradio.com/oral-treatment-for-rare-disease-pediatric-growth-hormone-deficiency-with-rick-hawkins-lumos-pharma Rick Hawkins, CEO, and Chairman of Lumos Pharma is developing an oral compound to treat idiopathic pediatric growth hormone deficiency. Currently, the only...

www.excelmale.com

Nelson Vergel · Jul 17, 2025

Thread 'Oral GH Booster MK-677 (ibutamoren) Side Effects and Benefits'

Jan 23, 2016

J Clin Endocrinol Metab. 1998 Feb;83(2):362-9.

Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure.

Svensson J1, Lönn L, Jansson JO, Murphy G, Wyss D, Krupa D, Cerchio K, Polvino W, Gertz B, Boseaus I, Sjöström L, Bengtsson BA.

Abstract

Obesity is associated with blunted GH secretion, unfavorable body composition, and increased cardiovascular mortality. The objective of this study was to investigate the effects of oral treatment with the GH secretagogue MK-677 on GH secretion...

Nelson Vergel · Jul 17, 2025

Thread 'Phase 2 Trial Evaluating LUM-201 for Treatment of Growth Hormone Deficiency'

Aug 3, 2024

Pisit “Duke” Pitukcheewanont, MD, Chief Medical Officer for Lumos Pharma, discusses a phase 2 trial evaluating LUM-201 (ibutamoren) for treatment of growth hormone deficiency.

Pediatric growth hormone deficiency (PGHD) is a rare condition characterized by insufficient amounts of growth hormone produced by the pituitary gland. GHD can be acquired but is often congenital, with possible mutations in the POU1F1/Pit1 , PROP1 GHRH and GH1 genes.

Signs and symptoms may include:

- Short stature
- Slow growth or absence of growth
- Absent or delayed sexual...

Nelson Vergel · Jul 17, 2025

Thread 'Lumos Hopes Its Oral Alternative to HGH Will Fuel Its Growth'

Aug 19, 2023

Lumos Hopes Its Oral Alternative to HGH Will Fuel Its Growth - RARECast | iHeart

<p>Growth hormone deficiency is a rare condition that is the result of inadequate secretion of growth hormone from the pituitary gland. Though recombinant human growth hormone has long been used to treat people with pediatric growth hormone deficiency, it requires either daily or weekly...

www.iheart.com

Growth hormone deficiency is a rare condition that is the result of inadequate secretion of growth hormone from the pituitary gland. Though recombinant human growth hormone has long been used to treat people with pediatric growth hormone deficiency, it requires either daily or weekly injections and when injections are missed, results can be sub-optimal. Lumos Pharma is developing a once-daily oral therapy that works by promoting secretion of growth hormone. We spoke to...